JP2021510162A5 - - Google Patents

Info

Publication number
JP2021510162A5
JP2021510162A5 JP2020538051A JP2020538051A JP2021510162A5 JP 2021510162 A5 JP2021510162 A5 JP 2021510162A5 JP 2020538051 A JP2020538051 A JP 2020538051A JP 2020538051 A JP2020538051 A JP 2020538051A JP 2021510162 A5 JP2021510162 A5 JP 2021510162A5
Authority
JP
Japan
Prior art keywords
modified
polypeptide
tfr
amino acid
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020538051A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021510162A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/012990 external-priority patent/WO2019140050A1/en
Publication of JP2021510162A publication Critical patent/JP2021510162A/ja
Publication of JP2021510162A5 publication Critical patent/JP2021510162A5/ja
Priority to JP2023190569A priority Critical patent/JP2024016195A/ja
Priority to JP2025163460A priority patent/JP2026010691A/ja
Pending legal-status Critical Current

Links

JP2020538051A 2018-01-10 2019-01-10 トランスフェリン受容体結合ポリペプチド及びその使用 Pending JP2021510162A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023190569A JP2024016195A (ja) 2018-01-10 2023-11-08 トランスフェリン受容体結合ポリペプチド及びその使用
JP2025163460A JP2026010691A (ja) 2018-01-10 2025-09-30 トランスフェリン受容体結合ポリペプチド及びその使用

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201862615914P 2018-01-10 2018-01-10
US62/615,914 2018-01-10
US201862631281P 2018-02-15 2018-02-15
US62/631,281 2018-02-15
US201862682639P 2018-06-08 2018-06-08
US62/682,639 2018-06-08
US201862721275P 2018-08-22 2018-08-22
US62/721,275 2018-08-22
PCT/US2019/012990 WO2019140050A1 (en) 2018-01-10 2019-01-10 Transferrin receptor-binding polypeptides and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023190569A Division JP2024016195A (ja) 2018-01-10 2023-11-08 トランスフェリン受容体結合ポリペプチド及びその使用

Publications (2)

Publication Number Publication Date
JP2021510162A JP2021510162A (ja) 2021-04-15
JP2021510162A5 true JP2021510162A5 (https=) 2022-02-07

Family

ID=65441044

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020538051A Pending JP2021510162A (ja) 2018-01-10 2019-01-10 トランスフェリン受容体結合ポリペプチド及びその使用
JP2023190569A Pending JP2024016195A (ja) 2018-01-10 2023-11-08 トランスフェリン受容体結合ポリペプチド及びその使用
JP2025163460A Pending JP2026010691A (ja) 2018-01-10 2025-09-30 トランスフェリン受容体結合ポリペプチド及びその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023190569A Pending JP2024016195A (ja) 2018-01-10 2023-11-08 トランスフェリン受容体結合ポリペプチド及びその使用
JP2025163460A Pending JP2026010691A (ja) 2018-01-10 2025-09-30 トランスフェリン受容体結合ポリペプチド及びその使用

Country Status (15)

Country Link
US (1) US20210130485A1 (https=)
EP (1) EP3737701A1 (https=)
JP (3) JP2021510162A (https=)
KR (1) KR102720600B1 (https=)
CN (1) CN111741977A (https=)
AR (1) AR114077A1 (https=)
AU (1) AU2019207735A1 (https=)
BR (1) BR112020013921A2 (https=)
CA (1) CA3088157A1 (https=)
CO (1) CO2020009827A2 (https=)
IL (1) IL275969A (https=)
MX (1) MX2020007389A (https=)
SG (1) SG11202006420TA (https=)
TW (1) TW201934573A (https=)
WO (1) WO2019140050A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110506055A (zh) 2017-02-17 2019-11-26 戴纳立制药公司 工程改造的转铁蛋白受体结合多肽
CR20200129A (es) 2017-10-02 2020-08-22 Denali Therapeutics Inc Proteínas de fusión que comprenden enzimas de terapia de reemplazo de enzimas
CN109705211B (zh) 2017-10-26 2020-08-18 苏州复融生物技术有限公司 一种IgG1 Fc单体及其应用
WO2020037150A2 (en) * 2018-08-16 2020-02-20 Denali Therapeutics Inc. Engineered bispecific proteins
BR112021015656A2 (pt) 2019-02-20 2021-10-05 Denali Therapeutics Inc. Anticorpos anti-trem2 e métodos de uso dos mesmos
PH12022551598A1 (en) 2019-12-23 2023-11-20 Denali Therapeutics Inc Progranulin variants
JP2023512450A (ja) 2020-01-13 2023-03-27 デナリ セラピューティクス インコーポレイテッド 抗ｔｒｅｍ２抗体及びその使用方法
EP4229192A1 (en) 2020-10-14 2023-08-23 Denali Therapeutics Inc. Fusion proteins comprising sulfoglucosamine sulfohydrolase enzymes and methods thereof
CN112341538A (zh) * 2020-10-27 2021-02-09 苏州复融生物技术有限公司 一种Fc单体多肽及其应用
CA3217756A1 (en) * 2021-05-05 2022-11-10 Jonathan S. Wall Peptide-fc fusions for treating amyloid disorders
WO2023279099A1 (en) * 2021-07-01 2023-01-05 Denali Therapeutics Inc. Oligonucleotide conjugates targeted to the transferrin receptor
CN115873127B (zh) * 2021-11-26 2026-04-10 深圳科兴药业有限公司 重组长效人生长激素融合蛋白及其制备方法和用途
JP2025503437A (ja) * 2021-12-17 2025-02-04 デナリ セラピューティクス インコーポレイテッド ポリペプチド操作、ライブラリー、ならびに操作されたｃｄ９８重鎖及びトランスフェリン受容体結合ポリペプチド
WO2024006976A2 (en) * 2022-07-01 2024-01-04 Denali Therapeutics Inc. Transferrin receptor binding molecule conjugates for delivery of oligonucleotides to cells
IL317261A (en) 2022-07-29 2025-01-01 Regeneron Pharma Non-human animals containing a modified transferrin receptor locus
KR20250058123A (ko) 2022-07-29 2025-04-29 리제너론 파마슈티칼스 인코포레이티드 항-TfR:페이로드 융합 및 이의 사용 방법
CN120659627A (zh) 2022-07-29 2025-09-16 瑞泽恩制药公司 用于转铁蛋白受体（tfr）介导的脑和肌肉递送的组合物和方法
CA3263388A1 (en) 2022-07-29 2024-02-01 Regeneron Pharmaceuticals, Inc. VIRAL PARTICLES RETRIBUTED TO TRANSFERRIN RECEPTOR 1
WO2024130116A2 (en) * 2022-12-16 2024-06-20 Denali Therapeutics Inc. Methods and compositions related to engineered transferrin receptor‑binding molecules
CN120958020A (zh) 2023-03-24 2025-11-14 戴纳立制药公司 Aβ靶向蛋白和使用方法
IL326018A (en) 2023-07-28 2026-03-01 Regeneron Pharma Introduction of anti-TFR:GAA and anti-CD63:GAA for the treatment of Pompe disease
US20250049896A1 (en) 2023-07-28 2025-02-13 Regeneron Pharmaceuticals, Inc. Anti-tfr:acid sphingomyelinase for treatment of acid sphingomyelinase deficiency

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981217A (en) * 1995-12-11 1999-11-09 Mayo Foundation For Medical Education And Research DNA encoding TGF-β inducible early factor-1 (TIEF-1), a gene expressed by osteoblasts
AU9063801A (en) * 2000-09-06 2002-03-22 Aventis Pharma Sa Methods and compositions for diseases associated with amyloidosis
US20060130158A1 (en) * 2002-08-30 2006-06-15 Turner Andrew J Modified transferrin fusion proteins comprising duplicate transferrin amino or carboxy terminal domains
CA2512729C (en) * 2003-01-09 2014-09-16 Macrogenics, Inc. Identification and engineering of antibodies with variant fc regions and methods of using same
EP1697520A2 (en) * 2003-12-22 2006-09-06 Xencor, Inc. Fc polypeptides with novel fc ligand binding sites
CN101511868B (zh) * 2006-07-24 2013-03-06 比奥雷克西斯制药公司 毒蜥外泌肽融合蛋白
WO2013177062A2 (en) * 2012-05-21 2013-11-28 Genentech, Inc. Methods for improving safety of blood-brain barrier transport
EP3594240B1 (en) * 2013-05-20 2023-12-06 F. Hoffmann-La Roche AG Anti-transferrin receptor antibodies and methods of use
WO2016077806A1 (en) * 2014-11-13 2016-05-19 AskGene Pharma, Inc. Fusion proteins with dual receptor agonist activities
US10508151B2 (en) * 2014-11-19 2019-12-17 Genentech, Inc. Anti-transferrin receptor antibodies and methods of use
EA039366B1 (ru) * 2015-06-24 2022-01-19 Джей Си Ар ФАРМАСЬЮТИКАЛЗ КО., ЛТД. Антитело к рецептору трансферрина человека, проникающее через гематоэнцефалический барьер
AR106189A1 (es) * 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
US10457717B2 (en) * 2017-02-17 2019-10-29 Denali Therapeutics Inc. Engineered polypeptides
SG11201907422RA (en) * 2017-02-17 2019-09-27 Denali Therapeutics Inc Anti-tau antibodies and methods of use thereof
CN110506055A (zh) * 2017-02-17 2019-11-26 戴纳立制药公司 工程改造的转铁蛋白受体结合多肽
WO2018210898A1 (en) * 2017-05-18 2018-11-22 F. Hoffmann-La Roche Ag Reduction of application-related side reaction of a therapeutic antibody
WO2018237338A1 (en) * 2017-06-23 2018-12-27 Denali Therapeutics Inc. Anti-alpha-synuclein antibodies and methods of use thereof

Similar Documents

Publication Publication Date Title
JP2021510162A5 (https=)
JP2021533779A5 (https=)
JP2024150674A5 (https=)
ES2371072T3 (es) Proteínas de fusión análogas de glp-1.
JP2021534220A5 (https=)
ES2298785T3 (es) Proteinas de fusion.
JP2021527656A5 (https=)
EP3576789B1 (en) MONOMERIC HUMAN IgG1 Fc AND BISPECIFIC ANTIBODIES
JP2007505643A5 (https=)
EP2847229B1 (en) Single domain binding molecule
JP7189142B2 (ja) 抗ヒトアネキシンａ１抗体
KR20250152665A (ko) Ｆc-함유 폴리펩타이드의 안정화
JP2023040169A5 (https=)
RU2015110250A (ru) ВАРИАНТЫ FcγRIIB-СПЕЦИФИЧЕСКОЙ Fc-ОБЛАСТИ
JP2021521781A5 (https=)
AU2024201813A1 (en) Blood-brain barrier transmigrating compounds and uses thereof
JP2023545707A5 (https=)
CA3096097A1 (en) Growth differentiation factor 15 fusion proteins
JP2024539139A5 (https=)
CN111448217A (zh) 双特异性抗原结合构建体
JP2022530068A5 (https=)
JP2022525661A5 (https=)
KR20220157910A (ko) Gdf15 변이체 및 glp-1 수용체 작용제를 포함하는 병용 투여용 조성물
JP2024546129A5 (https=)
US20240279324A1 (en) Multispecific antagonists